An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases

被引:74
作者
Carlson, GB
Calvanese, CB
Partin, AW
机构
[1] DIANON Syst, Technol & Business Dev, Stratford, CT 06615 USA
[2] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
关键词
D O I
10.1016/S0090-4295(98)00205-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To (1) determine if patient age and total prostate-specific antigen (PSA) levels could enhance the ability of percent free PSA to distinguish prostate cancer from benign prostate disease within the 4.0 to 20 ng/mL total PSA range; (2) define the probability of prostate cancer based on patient age, total PSA, and percent free PSA; and (3) define a probability cutoff that distinguishes benign from malignant prostate disease. Methods. The 3773 urologically referred patients with serum PSA values between 4.0 and 20 ng/mL had a sextant biopsy diagnosed as either prostatic carcinoma (1234) or benign prostatic disease (2539) within 60 days of serum specimen collection. We created a logistic regression model, using patient age, total PSA, and percent free PSA, to assign a probability of prostate cancer, and tested the model on an additional data set (525 patients) to calculate sensitivity and specificity. Results. An 18% probability cutoff detected 95% of malignant biopsies and identified 34% of negative biopsies in the validation set. This approach yielded an 11% percentage point increase in specificity over percent free PSA alone. A 20% probability cutoff detected 90% of malignant cases and identified 42% of negative biopsies. Conclusions. A prostate cancer probability based on age, total PSA, and percent free PSA is more effective than percent free PSA alone in differentiating benign prostate disease from prostate cancer. This model may assist physicians and patients regarding the need for biopsy. UROLOGY 52: 455-461, 1998. (C) 1998, Elsevier Science Inc, All rights reserved.
引用
收藏
页码:455 / 461
页数:7
相关论文
共 23 条
[1]  
[Anonymous], AHCPR PUBLICATION
[2]  
Catalona William J., 1997, Journal of Urology, V157, P111
[3]  
CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214
[4]   COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].
CATALONA, WJ ;
RICHIE, JP ;
AHMANN, FR ;
HUDSON, MA ;
SCARDINO, PT ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290
[5]   Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer [J].
Chen, YT ;
Luderer, AA ;
Thiel, RP ;
Carlson, G ;
Cuny, CL ;
Soriano, TE .
UROLOGY, 1996, 47 (04) :518-524
[6]   SERUM PROSTATE-SPECIFIC ANTIGEN COMPLEXED TO ALPHA-1-ANTICHYMOTRYPSIN AS AN INDICATOR OF PROSTATE-CANCER [J].
CHRISTENSSON, A ;
BJORK, T ;
NILSSON, O ;
DAHLEN, U ;
MATIKAINEN, MT ;
COCKETT, ATK ;
ABRAHAMSSON, PA ;
LILJA, H .
JOURNAL OF UROLOGY, 1993, 150 (01) :100-105
[7]   PROSTATE-CANCER DETECTION IN A CLINICAL UROLOGICAL PRACTICE BY ULTRASONOGRAPHY, DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN [J].
COONER, WH ;
MOSLEY, BR ;
RUTHERFORD, CL ;
BEARD, JH ;
POND, HS ;
TERRY, WJ ;
IGEL, TC ;
KIDD, DD .
JOURNAL OF UROLOGY, 1990, 143 (06) :1146-1154
[8]   Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer [J].
Elgamal, AAA ;
Cornillie, FJ ;
VanPoppel, HP ;
VandeVoorde, WM ;
McCabe, R ;
Baert, LV .
JOURNAL OF UROLOGY, 1996, 156 (03) :1042-1047
[9]  
Hosmer D., 1989, Applied Logistic Regression, V1st, DOI DOI 10.1097/00019514-200604000-00003
[10]   CLINICAL USE OF PROSTATE SPECIFIC ANTIGEN IN PATIENTS WITH PROSTATE-CANCER [J].
HUDSON, MA ;
BAHNSON, RR ;
CATALONA, WJ .
JOURNAL OF UROLOGY, 1989, 142 (04) :1011-1017